Amytrx Therapeutics,

Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.